After J.P. Morgan and William Blair gave Bluebird Bio (NASDAQ: BLUE) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Bluebird Bio yesterday. The company’s shares closed yesterday at $122.70.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 11.9% and a 59.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $151.17 average price target, which is a 23.2% upside from current levels. In a report issued on June 14, J.P. Morgan also assigned a Buy rating to the stock with a $195 price target.
See today’s analyst top recommended stocks >>
Based on Bluebird Bio’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $164 million. In comparison, last year the company had a GAAP net loss of $115 million.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is neutral on the stock. Last month, Jason Cole, the Chief Operating and of BLUE bought 562 shares for a total of $28,387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
